Guidelines for Medical Treatment for Stroke Prevention

Clinical Guidelines1 July 1994Guidelines for Medical Treatment for Stroke PreventionFREEAmerican College of Physicians.American College of Physicians.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-1-199407010-00009 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The numbers in square brackets are cross-references to the numbered paragraphs in the review article "Medical Treatment for Stroke Prevention" (see pages 41-53).Stroke includes various disorders that lead to the destruction of brain tissue, functional disability, and often death. The most common strokes result from atherothrombosis in the extracranial and larger intracranial arteries. Approximately 30% of ischemic strokes are of this origin. Cardioembolic strokes account for 20% to 25% of all ischemic strokes. Intracardiac thrombi secondary either to myocardial infarction or atrial fibrillation are the two most common causes of such strokes. Lacunar strokes account for 15% to 20% of ischemic lesions and are most commonly caused by the small vessel changes associated with hypertension of long duration. The remaining 30% of ischemic strokes are secondary to less common conditions or are of unknown origin. Approximately 15% of strokes result from cerebral hemorrhage, usually due to rupture of aneurysms or other vascular malformations, hypertensive arterial disease, and "lobar" hemorrhages in the elderly due to amyloid angiopathy.Therapeutic interventions directed at general, modifiable risk factors for stroke should be part of any effort to reduce the risk for stroke, regardless of whether the patient receives more specific medical or surgical treatment. These potentially modifiable risk factors include hypertension (including isolated systolic hypertension), heart disease, cigarette smoking, diabetes mellitus, heavy alcohol use, and hypercholesterolemia [2.1.1]. Several conditions are associated with an especially high risk for stroke and are potentially amenable to medical treatment, including carotid artery stenosis in asymptomatic patients, atrial fibrillation, transient ischemic attacks (TIAs) or stroke, and previous myocardial infarction [2.1.2].Treatment Strategies for Stroke PreventionThe question of medical treatment for stroke prevention must be considered in the context of surgical options, particularly carotid endarterectomy. Three recently completed studies have indicated that when surgery can be done in a low-risk setting (total perioperative stroke and death rate less than 6%), symptomatic patients who have anterior circulation TIAs or minor completed strokes and carotid stenosis greater than 70% (by strict measurement criteria) benefit from carotid endarterectomy. The evidence is less clear for patients with lower degrees of stenosis or asymptomatic patients with high degrees of stenosis. On average, patients with less than 30% stenosis have been shown to have worse outcomes with carotid endarterectomy [2.2].Medical treatments for stroke prevention include anticoagulation (for example, warfarin) and platelet antiaggregants (for example, aspirin and ticlopidine). Additional interventions for stroke prevention include methods for controlling risk factors, such as management of hypertension, smoking cessation, and control of blood cholesterol.RecommendationsRecommendations are graded A, B, or C according to the level of evidence that supports them. Grade A recommendations are supported by one or more level I studies or by a meta-analysis where the lower limit of the confidence interval for the effect of treatment exceeds the minimal clinically significant benefit. Grade B recommendations are supported by one or more level II studies or by a meta-analysis where the estimate of treatment effect exceeds the minimal clinically significant benefit but the lower limit of the confidence interval does not. Grade C recommendations are supported by published data other than randomized trials including secondary analyses of level I or II studies. Level I studies are randomized trials with low false-positive or low false-negative errors, or both. Level II studies are randomized trials with high false-positive and high false-negative errors.Based on the evidence cited, several recommendations can be supported.1. Nonvalvular atrial fibrillation: Warfarin is the drug of choice for patients who are candidates for anticoagulation (grade A recommendation). However, patients younger than 60 years without specific clinical or echocardiographic risk factors have a low risk for stroke and do not need treatment with warfarin (grade C recommendation). To achieve an acceptable benefit-to-risk ratio, it is crucial to carefully monitor the intensity of anticoagulation based on the international normalized ratio (INR), aiming for a ratio approximately between 2 and 3 (grade C recommendation). For patients unwilling or unable to take warfarin, aspirin is an appropriate alternative (grade A recommendation). The dose of 325 mg/d is supported by available evidence (grade A recommendation). For patients older than 75 years, aspirin may not be effective (grade C recommendation). Data are currently unavailable on the effectiveness of aspirin in lower-risk patients, such as those younger than 60 years without specific clinical or echocardiographic risk factors [4.1.2, 4.2.1].2. Transient ischemic attack and stroke: Aspirin is effective in reducing the risk for stroke in patients with TIA and minor stroke (grade A recommendation); however, the benefit-to-risk ratio is approximately 5:2. All aspirin doses studied have been found to be similarly effective, which suggests that decisions about dose should be based on patient tolerance (grade C recommendation). No evidence suggests that aspirin reduces the risk for stroke in patients who have had major stroke, but aspirin therapy is a reasonable option (grade C recommendation). Patients who do not respond to or tolerate aspirin are candidates for ticlopidine (grade A recommendation). Patients offered ticlopidine must be willing to accept the supervision and expense associated with this agent [4.1.3, 4.2.2].3. Previous myocardial infarction: Warfarin has been shown to reduce the rate of stroke in patients who have had myocardial infarction (grade A recommendation). However, this recommendation is tempered by the high rate of major complications in several studies. The resulting estimate of benefit-to-risk ratio is 3:2. These high complication rates may be caused by the use of relatively high-intensity anticoagulation in the included studies (INR, 2.5 to 4.8). Lower levels of anticoagulation are safer and, if as effective as the studied doses, would make warfarin a clear recommendation (grade C recommendation). Aspirin is an alternative treatment strategy for stroke reduction in patients who have had myocardial infarction (grade B recommendation); however, the benefits of this are likely to be small. For patients who have had myocardial infarction, neither anticoagulation nor antiplatelet agents are specifically recommended for stroke reduction. However, use of these agents may be justified on the basis of reduction in all nonfatal vascular events [4.1.4, 4.2.3].RationaleThese recommendations are primarily based on data from randomized, controlled trials indicating that three agents significantly reduce the risk for stroke in specific high-risk patients: warfarin for patients with atrial fibrillation or myocardial infarction, aspirin for patients with TIA or minor completed stroke, and ticlopidine for patients with TIA and completed stroke. However, the clinical decision to use medical therapy for stroke prevention is complicated by the potential risk of complications, some of which may be fatal. These recommendations are based ultimately on a judgment about when benefits appear to sufficiently outweigh risks. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: These guidelines were authored by David B. Matchar, MD; Douglas C. McCrory, MD; Henry J.M. Barnett, MD; John R. Feussner, MD, and were authored for the Health and Public Policy Committee by the Clinical Efficacy Assessment Subcommittee: Ernest L. Mazzaferri, MD, Chair; John R. Feussner, MD; Edward J. Huth, MD; Gerald R. Kerby, MD; Francis J. Klocke, MD; Col. Michael J. Kussman, MD; Keith I. Marton, MD; Albert G. Mulley, Jr., MD; Alvin I. Mushlin, MD; Valerie Anne Palda, MD;George E. Thibault, MD. Members of the Health and Public Policy Committee were Gerald E. Thomson, MD, Chair; Charles E. Harrison, Jr., MD; Christine K. Cassel, MD; David J. Gullen, MD; Ernest L. Mazzaferri, MD; James R. Webster, Jr., MD; Whitney Addington, MD; Robert Berenson, MD; Nancy E. Gary, MD; Sheldon Greenfield, MD; L. Julian Haywood, MD; Ana Maria Lopez, MD; Mack V. Traynor, Jr., MD. These guidelines were approved by the Board of Regents on 21 November 1993.Corresponding Author: Linda Johnson White, Director, Department of Scientific Policy, American College of Physicians, Independence Mall West, Sixth Street at Race, Philadelphia, PA 19106-1572. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byİskemik inmede ekokardiyografi bulgularının inme şiddeti, hemorajik transformasyon ve kısa dönem prognoz ile ilişkisiA Home-Based Adaptive Collaborative System for Stroke Patient RehabilitationCosto-efectividad de dabigatrán comparado con warfarina para el tratamiento de pacientes con fibrilación auricular no valvularBalloons in Endovascular NeurosurgeryEfficacy of the CHADS2 Scoring System to Assess Left Atrial Thrombogenic Milieu Risk Before Cardioversion of Non-Valvular Atrial FibrillationTrends in Risk Factor Prevalence and Management Before First StrokeIntracranial angioplasty with Gateway-Wingspan system for symptomatic atherosclerotic stenosis: preliminary results of 27 Chinese patientsRole of the CHADS2Score in the Evaluation of Thromboembolic Risk in Patients With Atrial Fibrillation Undergoing Transesophageal Echocardiography Before Pulmonary Vein IsolationThe Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial FibrillationStroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II studyBMS-204352: A Potassium Channel Opener Developed for the Treatment of StrokeUsing Systematic Reviews to Inform Decision MakersUsing Systematic Reviews to Inform Decision MakersAspirin use for primary and secondary prophylaxis of cardiovascular diseaseWarfarin Therapy for an Octogenarian Who Has Atrial FibrillationBrian F. Gage, MD, MSc, Stephan D. Fihn, MD, MPH, and Richard H. White, MDAspirin Use Among Adults With DiabetesSecondary Stroke Prevention in Atrial FibrillationAntithrombotic Management of Atrial Fibrillation for Stroke Prevention in Older PeopleOpen label tissue plasminogen activator for stroke: The Oregon experienceRisk Assessment and Anticoagulation for Primary Stroke Prevention in Atrial FibrillationIschemic stroke preventionVitamin K: A Practical Guide to the Dietary Management of Patients on WarfarinCost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial FibrillationThe Sequelae of Hospitalization for Ischemic Stroke Among Older AdultsWarfarin Use Among Patients With Atrial FibrillationPrimary Stroke Prevention in Nonvalvular Atrial Fibrillation: Implementing the Clinical Trial FindingsRisk FactorsKnowledge of Risk Among Patients at Increased Risk for StrokeStratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: The relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrastMCardiac Problems in Patients with Neurologic Disease 1 July 1994Volume 121, Issue 1Page: 54-55KeywordsAspirinAtrial fibrillationHypertensionIschemic strokeMedical risk factorsMyocardial infarctionRandomized trialsStenosisStrokeTransient ischemic attacks ePublished: 15 August 2000 Issue Published: 1 July 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...